Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06858306 · ClinicalTrials.gov registry record

SPHERE Per-AF Post-Approval Study

A clinical trial of Persistent Atrial Fibrillation, sponsored by Medtronic Cardiac Ablation Solutions.

Recruiting
Registry status
200
Enrollment target
12
Study locations

NCT06858306: Recruiting study of Persistent Atrial Fibrillation, sponsored by Medtronic Cardiac Ablation Solutions.

NCT06858306 is a study of Persistent Atrial Fibrillation that is actively recruiting participants, run by Medtronic Cardiac Ablation Solutions. The registered enrollment target is 200 participants, below the 1,247-participant average among 15 other Persistent Atrial Fibrillation trials with a reported enrollment target (84% lower). The trial reports 12 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06858306, a study of Persistent Atrial Fibrillation, is actively recruiting participants, sponsored by Medtronic Cardiac Ablation Solutions.

RECRUITING
Registry status
200 participants
Enrollment target
12
Study locations

Study Summary

SPHERE Per-AF Post-Approval Study is a prospective, multi-center, non-randomized, observational trial. Subjects will be treated with the Sphere-9™ Catheter and Affera™ Ablation System and followed through 36 months.

Primary Outcome

Estimate the primary safety adverse event (AE) rate for ablation using the Sphere-9™ Catheter and Affera™ Ablation System.

Interventions

  • DEVICE Sphere-9™ Catheter and Affera™ Ablation System

Study Locations (12)

Minnesota

  • Minneapolis Heart Institute Foundation - Minneapolis
  • Mayo Clinic - Rochester

Pennsylvania

  • Doylestown Health Cardiology - Doylestown
  • Allegheny General Hospital - Pittsburgh

Texas

  • Texas Health Resources - Fort Worth
  • Houston Methodist Hospital - Houston

Virginia

  • University of Virginia Medical Center - Charlottesville
  • Centra Medical Group Stroobants Cardiovascular Center - Lynchburg

Alabama

  • University of Alabama at Birmingham Hospital - Birmingham

Florida

  • Sarasota Memorial Hospital - Sarasota

New York

  • Montefiore Medical Center - New York

Ohio

  • OhioHealth - Columbus

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2025-09-25
Est. Completion 2030-10

What NCT06858306 shows while recruiting

NCT06858306 is an observational study that tracks outcomes without assigning an intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 1,247-participant average among 15 other Persistent Atrial Fibrillation trials with a reported enrollment target (84% lower).

The record links to 1 condition, with Persistent Atrial Fibrillation appearing as the primary indexed condition, and to 1 intervention - of which Sphere-9™ Catheter and Affera™ Ablation System is the first listed.

NCT06858306 lists 12 locations in 8 states (Minnesota, Pennsylvania, Texas).

Frequently Asked Questions

What is clinical trial NCT06858306 about?

NCT06858306 is a clinical study titled "SPHERE Per-AF Post-Approval Study". SPHERE Per-AF Post-Approval Study is a prospective, multi-center, non-randomized, observational trial. Subjects will be treated with the Sphere-9™ Catheter and Affera™ Ablation System and followed through 36 months.

What is the current status of trial NCT06858306?

This trial is currently recruiting. The enrollment target is 200 participants. The study started on 2025-09-25. Estimated completion is 2030-10.

What conditions does trial NCT06858306 study?

This clinical trial studies the following conditions: Persistent Atrial Fibrillation.

What interventions are being tested in trial NCT06858306?

The interventions under investigation include: Sphere-9™ Catheter and Affera™ Ablation System (DEVICE).

Who is sponsoring clinical trial NCT06858306?

This trial is sponsored by Medtronic Cardiac Ablation Solutions, which has 20 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06858306 being conducted?

This trial has 12 study locations across Alabama, Florida, Minnesota, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Persistent Atrial Fibrillation

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06858306's enrollment target sits among peer trials

200 10th of 15 higher than 5 of 15 other Persistent Atrial Fibrillation trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Persistent Atrial Fibrillation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00107289 · 200 participants · Phase 2

    Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma

  • NCT00109174 · 200 participants · NA

    MRS Measurement of Glutamate and GABA Metabolism in Brain

  • NCT00177268 · 200 participants

    Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research

  • NCT00493688 · 200 participants

    A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06858306, the US trial registry maintained by the National Library of Medicine. NCT06858306 (mid enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.